首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1084548

Ciclesonide的全球市场: 规模，占有率，展望，机会分析(2022年～2028年)

Ciclesonide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月08日 | 出版商:

Coherent Market Insights | 英文 126 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球Ciclesonide的市场规模，由于过敏性鼻炎和气喘的高盛行率，主要地区的频繁产品认证，主要企业的策略性M&A增加等所促进。

本报告提供全球Ciclesonide市场调查，市场概要，市场规模和预测，趋势，成长要素，阻碍因素，各适应症、剂型、地区的分析，及竞争情形等资讯。

Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting B2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

However, some of the studies raised concerns regarding increased risk of pneumonia related to regular use of ICS in adult patients with chronic obstructive pulmonary disease. A study findings published in the Respirology Journal: 2013, revealed an increased risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma regularly taking ICS. This could potentially lead to restrict application of ciclesonide by patients during the forecast period.

Market Dynamics

Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2021, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.

Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

Key features of the study:

This report provides in-depth analysis of ciclesonide market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global ciclesonide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study includes AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics.
The global ciclesonide market report caters to various stakeholders in this industry including investors, researchers, ciclesonide manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the ciclesonide market.

Detailed Segmentation:

Global Ciclesonide Market, By Indication:
Allergy Rhinitis
Asthma
Global Ciclesonide Market, By Dosage Form:
Aerosol
Nasal Spray
Global Ciclesonide Market, By Geography:
North America
- By Country:
U.S.
Canada
- By Indication:
Allergy Rhinitis
Asthma
- By Dosage Form:
Aerosol
Nasal Spray
Europe
- By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
- By Indication:
Allergy Rhinitis
Asthma
- By Dosage Form:
Aerosol
Nasal Spray
Asia Pacific
- By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
- By Indication:
Allergy Rhinitis
Asthma
- By Dosage Form:
Aerosol
Nasal Spray
Latin America
- By Country:
Brazil
Mexico
Argentina
Rest of Latin America
- By Indication:
Allergy Rhinitis
Asthma
- By Dosage Form:
Aerosol
Nasal Spray
Middle East
- By Country:
GCC
Israel
Rest of Middle East
- By Indication:
Allergy Rhinitis
Asthma
- By Dosage Form:
Aerosol
Nasal Spray
Africa
- By Country:
North Africa
Central Africa
South Africa
- By Indication:
Allergy Rhinitis
Asthma
- By Dosage Form:
Aerosol
Nasal Spray
Company Profiles
AstraZeneca Plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments
- Strategies
Cipla Limited
Sun Pharmaceutical Industries Ltd.
Apotex Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Indication
- Market Snippet, By Dosage Form
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
New Product Approvals & Launches

4. Global Ciclesonide Market, By Indication, 2017-2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Allergy Rhinitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)

5. Global Ciclesonide Market, By Dosage Form, 2017-2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)

6. Global Ciclesonide Market, By Region, 2017-2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
North America
- Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
- Market Size and Forecast, By Country, 2017-2028, (US$ Million)
U.S.
Canada
Europe
- Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
- Market Size and Forecast, By Country, 2017-2028, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
- Market Size and Forecast, By Country, 2017-2028, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
- Market Size and Forecast, By Country, 2017-2028, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
- Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
- Market Size and Forecast, By Country, 2017-2028, (US$ Million)
North Africa
Central Africa
South Africa
Middle East
- Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
- Market Size and Forecast, By Country, 2017-2028, (US$ Million)
GCC Countries
Israel
Rest of Middle East

7. Competitive Landscape

Heat Map Analysis
Company Profiles
- AstraZeneca Plc
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Strategies
- Cipla Limited
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Strategies
- Sun Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Strategies
- Apotex Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Future Strategies

8. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

Ciclesonide的全球市场: 规模，占有率，展望，机会分析(2022年～2028年)

Ciclesonide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章调查目的、前提条件

第2章市场概要

第3章市场动态，法规，及趋势分析

第4章全球Ciclesonide市场:各适应症(2017年～2028年)

第5章全球Ciclesonide市场:各剂型(2017年～2028年)

第6章全球Ciclesonide市场:各地区(2017年～2028年)

第7章竞争情形

第8章 Section